Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis
Authors' conclusion
Our study provides insights based on robust mechanistic data for optimizing heart failure management and highlights the intricate interplay between diabetes, inflammation, aging, and cardiovascular health.
Study context
- Population
- Human cardiomyocyte AC16 cells exposed to normal and high glucose for 2 and 7 days; diabetic patients in selected RCTs
- Comparison
- Empagliflozin vs no empagliflozin in high-glucose-exposed cardiomyocytes
- Outcome
- Transcriptional inflammatory, metabolic and aging signatures in high-glucose-exposed human cardiomyocytes
Methodological detailsmeta-analysis of RCTs, in vitro, in silico
- Meta-analysis of RCTs
- In vitro
- In silico
Main finding
As reported in the abstract
- Empagliflozin reversed high-glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic and aging signatures
- In vitro data, meta-analyses of clinical inflammatory biomarkers and sequencing of pathological human heart tissues all support anti-inflammatory effects of empagliflozin systemically and directly on cardiomyocytes
Original publication
Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis. Eur J Heart Fail. Published 14 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →